|
Mr. DeLuccia joined MacroChem's Board in 2000 and accepted the position of President and Chief Executive Officer and Vice Chairman of the Board in June of 2003. He held that position until his appointment as Chairman in April 2008 following MacroChem’s acquisition of Virium Pharmaceuticals Inc. Mr. DeLuccia is the former President and Chief Executive Officer of Immunomedics Inc. a Nasdaq biopharmaceutical company focused on the development and commercialization of antibody diagnostic imaging and therapeutic products for cancer and infectious diseases. Prior to Immunomedics he was President of Sterling Winthrop Pharmaceuticals the U.S. subsidiary of Sanofi (now Sanofi-Aventis). Mr. DeLuccia began his career as a pharmaceutical sales representative for Pfizer and progressed to Vice President Marketing and Sales Operations for Pfizer's Roerig Division. He is also a member of the board of directors of IBEX Technologies a publicly traded (TSX Venture Exchange) pharmaceutical company that markets a series of proprietary enzymes (heparinases and chondroitinases) for research use as well as Heparinase I which is used in many leading hemostasis monitoring devices. Mr. DeLuccia holds both a B.S. and an M.B.A. in marketing from Iona College. | 